Could a Lab-Made antibody be the next acne breakthrough?
NCT ID NCT04856917
First seen Jun 24, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This Phase 2 trial tested a drug called imsidolimab (ANB019) in 123 people with moderate to severe acne. The drug is a lab-made antibody designed to reduce inflammation. Researchers measured how much facial acne lesions decreased over 12 weeks compared to a placebo. The goal is to see if this treatment is safe and effective for acne.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
imsidolimab (ANB019), a lab-made antibody
What this could lead to
If it works, this could offer a new treatment option for people with moderate to severe acne who don't respond to current therapies.
What could go wrong
This is an early Phase 2 trial with only 123 participants, so results may not apply to everyone. The drug may not reduce acne better than placebo, and side effects are still being studied.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACNE VULGARIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Site 10-101
San Antonio, Texas, 78213, United States
-
Site 10-102
College Station, Texas, 77845, United States
-
Site 10-103
Austin, Texas, 78759, United States
-
Site 10-104
Detroit, Michigan, 48202, United States
-
Site 10-105
Murfreesboro, Tennessee, 37130, United States
-
Site 10-106
Sherman Oaks, California, 91403, United States
-
Site 10-107
Tampa, Florida, 33613, United States
-
Site 10-108
Tampa, Florida, 33607, United States
-
Site 10-109
New Orleans, Louisiana, 70119, United States
-
Site 10-110
Portsmouth, New Hampshire, 03801, United States
-
Site 10-111
Fountain Valley, California, 92708, United States
-
Site 10-112
New Orleans, Louisiana, 70119, United States
-
Site 10-113
Sweetwater, Florida, 33172, United States
-
Site 10-114
Hot Springs, Arkansas, 71913, United States
-
Site 10-115
Waterloo, Ontario, N2J1C4, Canada